Form 4: Sangamo Therapeutics Director Karen L. Smith Receives Significant Equity Grants

Sangamo Therapeutics, Inc. Director Karen L. Smith was granted 25,000 restricted stock units and options to purchase 50,000 shares of common stock on June 12, 2025.

Summary

• Karen L. Smith, a Director of Sangamo Therapeutics, Inc. (SGMO), received equity grants on June 12, 2025.
• The grants include 25,000 shares of common stock in the form of Restricted Stock Units (RSUs) at a grant price of $0.
• These RSUs will fully vest on the earlier of June 12, 2026, or the day prior to the 2026 annual meeting of stockholders, contingent on Ms. Smith's continuous service.
• Additionally, Ms. Smith was granted options to purchase 50,000 shares of common stock with an exercise price of $0.503 per share.
• These options are immediately exercisable in full, but any unvested shares purchased are subject to certain repurchase rights by the Issuer upon cessation of continuous service.
• The options will vest in 12 successive equal monthly installments following the grant date, also subject to Ms. Smith's continuous service.
• Following these transactions, Ms. Smith beneficially owns 102,100 shares of common stock and 50,000 stock options.

Sentiment

Score: 7

Explanation: The document reports routine equity grants to a director, which is generally a positive sign for aligning interests and retaining talent. It's a standard compensation event, not indicative of major operational news, hence a moderately positive score.

Positives

• The equity grants align the director's financial interests with long-term shareholder value, incentivizing performance.
• The immediate exercisability of the stock options provides flexibility for the director, although vesting conditions apply.
• The grants indicate continued commitment and compensation for a key board member, which can be viewed positively for corporate stability.

Risks

• Vesting of both the 25,000 RSUs and the 50,000 stock options is contingent upon the Reporting Person's 'Continuous Service' with the Issuer, meaning the benefits are tied to her ongoing role.
• Unvested shares acquired through the exercise of the stock options are subject to repurchase rights by Sangamo Therapeutics, Inc. if the Reporting Person's continuous service ceases.

Future Outlook

The equity grants are designed to incentivize continued service and align the director's long-term interests with the company's performance, with vesting periods extending into 2026 for RSUs and option expiration in 2035.

Industry Context

This Form 4 filing reflects a standard practice of executive and director compensation within the biotechnology or pharmaceutical industry, where equity grants are commonly used to attract, retain, and incentivize key personnel by aligning their financial interests with the company's long-term success.

Corporate Governance

Related Party Transactions

• The grant of 25,000 Restricted Stock Units and 50,000 stock options to Karen L. Smith, a Director of Sangamo Therapeutics, Inc., constitutes a related party transaction as it involves compensation from the company to an insider.

Stakeholder Impact

• Shareholders: The grants align the director's financial interests with shareholder value creation, potentially leading to more focused long-term decision-making. However, it also represents potential future dilution upon vesting/exercise.
• Management/Directors: Directly impacts Karen L. Smith by providing significant equity compensation, incentivizing her continued service and performance.

Next Steps

• Vesting of 25,000 Restricted Stock Units on the earlier of June 12, 2026, or the day prior to the 2026 annual meeting of stockholders.
• Monthly vesting of 50,000 stock options over 12 installments following the grant date.
• Potential exercise of stock options by Karen L. Smith prior to their expiration on June 11, 2035.

Key Dates

Keywords

Sangamo Therapeutics, SGMO, Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, Stock Options, Director Compensation, Beneficial Ownership